| Literature DB >> 11901168 |
Ian J Glomski1, Margaret M Gedde, Albert W Tsang, Joel A Swanson, Daniel A Portnoy.
Abstract
Listeria monocytogenes is a facultative intracellular bacterial pathogen that escapes from a phagosome and grows in the host cell cytosol. The pore-forming cholesterol-dependent cytolysin, listeriolysin O (LLO), mediates bacterial escape from vesicles and is approximately 10-fold more active at an acidic than neutral pH. By swapping dissimilar residues from a pH-insensitive orthologue, perfringolysin O (PFO), we identified leucine 461 as unique to pathogenic Listeria and responsible for the acidic pH optimum of LLO. Conversion of leucine 461 to the threonine present in PFO increased the hemolytic activity of LLO almost 10-fold at a neutral pH. L. monocytogenes synthesizing LLO L461T, expressed from its endogenous site on the bacterial chromosome, resulted in a 100-fold virulence defect in the mouse listeriosis model. These bacteria escaped from acidic phagosomes and initially grew normally in cells and spread cell to cell, but prematurely permeabilized the host membrane and killed the cell. These data show that the acidic pH optimum of LLO results from an adaptive mutation that acts to limit cytolytic activity to acidic vesicles and prevent damage in the host cytosol, a strategy also used by host cells to compartmentalize lysosomal hydrolases.Entities:
Mesh:
Substances:
Year: 2002 PMID: 11901168 PMCID: PMC2173464 DOI: 10.1083/jcb.200201081
Source DB: PubMed Journal: J Cell Biol ISSN: 0021-9525 Impact factor: 10.539
Figure 1.Identification of amino acid residues that control the pH dependence of LLO hemolytic activity. (A) Alignment of domain 4 of LLO and PFO. Amino acid sequences from PFO (bottom of the gray boxes) were exchanged with the amino acids within LLO (top of the gray boxes). Each chimera is numbered from 1 to 12 at the bottom of the gray boxes. The star indicates the L461T mutation. (B) Analysis of the hemolytic activity of the 12 chimeric proteins, expressed in E. coli, represented as the ratio of the activities at pH 5.5 and 7.4. (C) Hemolytic units at pH 5.5 and 7.4 of 40 ng of purified histidine-tagged wild-type LLO, PFO, the domain 4 chimera, and the L461T LLO mutant. Error bars represent the standard deviation. (D) Alignment of 10 CDCs in the 461 region. Star and the gray box indicate position 461 in LLO. Empty boxes indicate identity. The listed toxins are from the following organisms: listeriolysin, L. monocytogenes; perfringolysin, C. perfringens; ivanolysin, L. ivanovi; seeligeriolysin, L. seeligeri; streptolysin, Streptococcus pyogenes; pneumolysin, S. pneumoniae, cereolysin, Bacillus cereus; alveolysin, Paenibacillus alvei; suilysin, S. suis; pyolysin, Arcanobacterium pyogenes.
b
| Strain | Lethal dose-50 | Percent phagosomal escape | Average pH | |
|---|---|---|---|---|
| No treatment | 0.5 μM bafilomycin A1 | |||
| Wild type (10403S) | 1–3 × 104b | 72 ± 2 | 23 ± 6 | 5.7 ± 0.3 |
| LLO-minus | 1 × 109 | 0 | 0 | ND |
| LLO L461T | >3 ×106 | 76 ± 2 | 25 ± 8 | 5.5 ± 0.2 |
The LLO-minus strain (2161) was published in Jones and Portnoy (1994a).
LD50 for 10403S was published in Portnoy et al. (1988).
Error indicates standard deviation.
Average represents 11 perforated phagosomes measured for wild type and 17 for LLO L461T.
Figure 2.Growth of bacteria within J774 cells and release of LDH by infected cells. (A and B) Growth of bacteria within the J774 macrophage-like cell line in the presence of 50 mg/ml gentamicin. Gentamicin kills extracellular bacteria. Colony-forming units at each time point represent the average ± SD of results from three coverslips. (C) LDH release into tissue culture medium was used to monitor perforation of the host cell plasma membrane. Release of LDH after infection of J774 cells by each strain was compared with total LDH determined after lysis with detergent. LDH release was determined for different exposures of the cultures to gentamicin, which kills intracellular bacteria when host cells have been permeabilized. Error bars represent the SD of three infections.
Figure 3.Assessment of host plasma membrane integrity using flow cytometry. (A–F) CD-1 murine BM∅s were stained with 2 μg/ml propidium iodide 7 h after infection with the indicated strains. The gray shaded histogram represents uninfected cells. The fluorescence range of cells scored as permeabilized, indicated by the marker M1, was defined by adding 106 hemolytic units of purified histidine-tagged LLO L461T to the macrophages. A total of 2.5 × 104 cells were scored in each assay; half are displayed in the histograms. The percentage of cells falling within the fluorescence range of marker M1 relative to the total number of cells counted is shown.
Figure 4.LLO secreted by intracellular [35S]Met-labeled LLO from J774 cells infected for 5 h was immunoprecipitated and examined using SDS-PAGE. Half of the protein was used to perform autoradiography, with a representative gel shown, and the other half was used for phosphorimaging. As published elsewhere (Moors et al., 1999; Decatur and Portnoy, 2000), two forms of LLO are observed, a full length 58-kD form and a truncated 55-kD form. Quantitation of the phosphorimaged samples is displayed on the bottom as pixel volume from full-length and the truncated form of LLO together. Quantitation of relative band intensity, versus wild type, is normalized for colony-forming units of each sample at the end of the 5-h experiment. The error measurement represents SD of the mean from three experiments.
Figure 5.Cell-to-cell spread of The diameter of bacterial plaques formed within L2 cell monolayers over 3 d was measured and expressed as a percentage of the diameter of wild-type plaques. ActA GGG is an L. monocytogenes strain with decreased actin-based motility. ΔplcA is an L. monocytogenes strain with an in-frame deletion in the gene encoding the bacterial phosphatidylinositol–specific phospholipase C, which leads to a reduced ability to escape from the phagosome. Diploid is a strain containing two copies of the gene coding for LLO. Error bars represent the SD of the mean from a minimum of three experiments. Representative wells are shown on the right.
Oligonucleotides and cloning strategies
| Number | Sequence 5′→3′ (including enzyme site) | Construct | Template | Cloning | Pair |
|---|---|---|---|---|---|
| 3140 | GGAATTCCATATGAAGGATGCATCTGCATTCAAT (Nde1) | His-LLO, p3570 | 10403S genomic DNA | B | 3232 |
| 3232 | CGGGATCCTTATTAGTGGTGGTGGTGGTGGTGTTCGATTG GATTATCTAC (BamH1) | His-LLO, p3570 | 10403S genomic DNA | B | 3140 |
| 3541 | GGAATTCCCATGGGAAAGGATATAACAGATAAAAATCA (Nco1) | His-PFO, p4167 | p1868 | B | 3542 |
| 3542 | CGGGATCCTTATTAGTGGTGGTGGTGGTGGTGATTGTAAG TAATACTAGATCCA (BamH1) | His-PFO, p4167 | p1868 | B | 3541 |
| 3543 | ACGCGTCGACTTATTAGTGGTGGTGGTGG (Sal1) | His-LLO(1-3)PFO4 | p1868 | S | 3578, 3575 |
| 3575 | GGAATTCCATATGAAGGATGCATCTGCA (Nde1) | His-LLO(1-3)PFO4 | p3570 | S | 3543, 3579 |
| 3578 | ACTATGATCTAAGTTTATTTTTCCATCTGTATAAGC | His-LLO(1-3)PFO4 | p1868 | S | 3543 |
| 3579 | GCTTATACAGATGGAAAAATAAACTTAGATCATAGT | His-LLO(1-3)PFO4 | p3570 | S | 3575 |
| 3740 | GGAGGATACGTTGCTCAATTCGAAGTAGCCTGGGATGAAG TAAATTATGAT | Chimera 1 | p3570 | Q | 3741 |
| 3741 | ATCATAATTTACTTCATCCCAGGCTACTTCGAATTGAGCAAC GTATCCTCC | Chimera 1 | p3570 | Q | 3740 |
| 3742 | AACATTTCTTGGGATGAAGTATCATATGACAAAGAAGGTAA CGAAATTGTTCAA | Chimera 2 | p3570 | Q | 3743 |
| 3743 | TTGAACAATTTCGTTACCTTCTTTGTCATATGATACTTCATCC CAAGAAATGTT | Chimera 2 | p3570 | Q | 3742 |
| 3744 | TATGATCCTGAAGGTAACGAAGTATTAACTCATAAAAACTG GAGCGAAAAC | Chimera 3 | p3570 | Q | 3745 |
| 3745 | GTTTTCGCTCCAGTTTTTATGAGTTAATACTTCGTTACCTTCA GGATCATA | Chimera 3 | p3570 | Q | 3744 |
| 3746 | AACGAAATTGTTCAACATAAAACATGGGATGGAAACAATAA AAGCAAGCTAGCT | Chimera 4 | p3570 | Q | 3747 |
| 3747 | AGCTAGCTTGCTTTTATTGTTTCCATCCCATGTTTTATGTTGA ACAATTTCGTT | Chimera 4 | p3570 | Q | 3746 |
| 3748 | CATAAAAACTGGAGCGAAAACTATCAAGATAAAACAGCTCA TTTCACATCGTCCATC | Chimera 5 | p3570 | Q | 3749 |
| 3749 | GATGGACGATGTGAAATGAGCTGTTTTATCTTGATAGTTTTC GCTCCAGTTTTTATG | Chimera 5 | p3570 | Q | 3748 |
| 3750 | AATAAAAGCAAGCTAGCTCATTATTCAACAGTAATCTATTTG CCTGGTAACGCG | Chimera 6 | p3570 | Q | 3751 |
| 3751 | CGCGTTACCAGGCAAATAGATTACTGTTGAATAATGAGCTA GCTTGCTTTTATT | Chimera 6 | p3570 | Q | 3750 |
| 3752 | GCTCATTTCACATCGTCCATCCCTCTTGAAGCTAACGCGAG AAATATTAATGTT | Chimera 7 | p3570 | Q | 3753 |
| 3753 | AACATTAATATTTCTCGCGTTAGCTTCAAGAGGGATGGACG ATGTGAAATGAGC | Chimera 7 | p3570 | Q | 3752 |
| 3754 | CCTGGTAACGCGAGAAATATTAGAATAAAAGCAAGAGAAT GCACTGGTTTAGCTTGG | Chimera 8 | p3570 | Q | 3755 |
| 3755 | CCAAGCTAAACCAGTGCATTCTCTTGCTTTTATTCTAATATTT CTCGCGTTACCAGG | Chimera 8 | p3570 | Q | 3754 |
| 3756 | TGGGAATGGTGGAGAGATGTAATTGATGACCGG | Chimera 9 | p3570 | Q | 3757 |
| 3757 | CCGGTCATCAATTACATCTCTCCACCATTCCCA | Chimera 9 | p3570 | Q | 3756 |
| 3758 | GGGAATGGTGGAGAACGGTAATTAGTGAATATGATGTTCC ACTTGTGAAAAATAGAAAT | Chimera 10 | p3570 | Q | 3759 |
| 3759 | ATTTCTATTTTTCACAAGTGGAACATCATATTCACTAATTACC GTTCTCCACCATTCCC | Chimera 10 | p3570 | Q | 3758 |
| 3760 | GACCGGAACTTACCACTTACAAATAATATAAATATCTCCATC TGGGGC | Chimera 11 | p3570 | Q | 3761 |
| 3761 | GCCCCAGATGGAGATATTTATATTATTTGTAAGTGGTAAGTT CCGGTC | Chimera 11 | p3570 | Q | 3760 |
| 3580 | AGATCCAGGGTATAAAGTGGTGCCCCAGATGGAGAT | Chimera 12 | p3570 | Q | 3581 |
| 3581 | ATCTCCATCTGGGGCACCACTTTATACCCTGGATCT | Chimera 12 | p3570 | Q | 3580 |
| 3799 | GAAAACAATAAAAGCAAGACAGCTCATTTCACATCGTCC | His-L461T and DP-L4017 | 10403S genomic DNA | QS | 3800 |
| 3800 | GGACGATGTGAAATGAGCTGTCTTGCTTTTATTGTTTTC | His-L461T and DP-L4017 | 10403S genomic DNA | QS | 3799 |
| 3931 | TTTCTGCAGAGAAACACGCGGATGAAATCGATA (Pst1) | DP-L4017 | 10403S genomic DNA | S | 3800, 3932 |
| 3932 | AAAAGAGCTCTCTGGAATTGAGGATGATTTCTTT (Sac1) | DP-L4017 | 10403S genomic DNA | S | 3799, 3931 |
Custom oligonucleotides were purchased from Operon Technologies and all restriction enzymes were from New England Biolabs, Inc.
Plasmid DNA was purified with a Qiagen plasmid midi kit and L. monocytogenes genomic DNA was isolated using a FastDNA® kit from Bio101.
B, basic PCR followed by plasmid ligation; S, splicing by overlap extension PCR and then plasmid ligation (Horton et al., 1990); Q, QuickchangeTM PCR (Stratagene).